Obio Technology (688238.SH) net loss of 325 million yuan in 2024, and the loss increased.

Obio Technology (688238.SH) released its 2024 annual performance report, with total operating income of 247 million yuan in 2024, a year-on-year increase of 20.60%; net loss attributable to the owners of the parent company was 325 million yuan, with an increased loss; net loss attributable to the owners of the parent company after deducting non-recurring gains and losses was 336 million yuan, with an increased loss; basic loss per share was 0.502 yuan. During the reporting period, the company actively faced various opportunities and challenges in the domestic biopharmaceutical field, adhered to the business philosophy of "customer first," and continued to effectively reserve customer resources. On the one hand, it constantly seeks new breakthroughs in business, maintaining stable growth in cell and gene therapy CRO business; on the other hand, it strives to promote the continuous release of the capacity advantages of the large-scale industrial base in Lingang, supports the progress of domestic cell and gene therapy drug development projects, and makes progress in expanding in the CDMO business field, order scale, project delivery, and other aspects. During the reporting period, the company's operating income achieved certain growth.